Search details
1.
Pan-Cancer Proteomics Analysis to Identify Tumor-Enriched and Highly Expressed Cell Surface Antigens as Potential Targets for Cancer Therapeutics.
Mol Cell Proteomics
; 22(9): 100626, 2023 09.
Article
in English
| MEDLINE | ID: mdl-37517589
2.
Molecular classification and biomarkers of outcome with immunotherapy in extensive-stage small-cell lung cancer: analyses of the CASPIAN phase 3 study.
Mol Cancer
; 23(1): 115, 2024 May 30.
Article
in English
| MEDLINE | ID: mdl-38811992
3.
Identifying homologous recombination deficiency in breast cancer: genomic instability score distributions differ among breast cancer subtypes.
Breast Cancer Res Treat
; 202(1): 191-201, 2023 Nov.
Article
in English
| MEDLINE | ID: mdl-37589839
4.
Uncovering variable neoplasms between ATM protein-truncating and common missense variants using 394 694 UK Biobank exomes.
Genes Chromosomes Cancer
; 61(9): 523-529, 2022 09.
Article
in English
| MEDLINE | ID: mdl-35394676
5.
Landscape of homologous recombination deficiencies in solid tumours: analyses of two independent genomic datasets.
BMC Cancer
; 22(1): 13, 2022 Jan 03.
Article
in English
| MEDLINE | ID: mdl-34979999
6.
Concordance of BRCA mutation detection in tumor versus blood, and frequency of bi-allelic loss of BRCA in tumors from patients in the phase III SOLO2 trial.
Gynecol Oncol
; 163(3): 563-568, 2021 12.
Article
in English
| MEDLINE | ID: mdl-34742578
7.
Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study.
Lancet Oncol
; 21(9): 1155-1164, 2020 09.
Article
in English
| MEDLINE | ID: mdl-32771088
8.
An evaluation of the challenges to developing tumor BRCA1 and BRCA2 testing methodologies for clinical practice.
Hum Mutat
; 39(3): 394-405, 2018 03.
Article
in English
| MEDLINE | ID: mdl-29215764
9.
Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes.
Br J Cancer
; 119(11): 1401-1409, 2018 11.
Article
in English
| MEDLINE | ID: mdl-30353044
10.
VarDict: a novel and versatile variant caller for next-generation sequencing in cancer research.
Nucleic Acids Res
; 44(11): e108, 2016 06 20.
Article
in English
| MEDLINE | ID: mdl-27060149
11.
BubbleTree: an intuitive visualization to elucidate tumoral aneuploidy and clonality using next generation sequencing data.
Nucleic Acids Res
; 44(4): e38, 2016 Feb 29.
Article
in English
| MEDLINE | ID: mdl-26578606
12.
Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in BRCA1 and/or BRCA2 in the PROfound Trial.
J Clin Oncol
; 42(5): 571-583, 2024 Feb 10.
Article
in English
| MEDLINE | ID: mdl-37963304
13.
Durvalumab ± Tremelimumab + Platinum-Etoposide in Extensive-Stage Small Cell Lung Cancer (CASPIAN): Outcomes by PD-L1 Expression and Tissue Tumor Mutational Burden.
Clin Cancer Res
; 30(4): 824-835, 2024 02 16.
Article
in English
| MEDLINE | ID: mdl-37801329
14.
Detection of BRCA1, BRCA2, and ATM Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound.
Clin Cancer Res
; 29(1): 81-91, 2023 01 04.
Article
in English
| MEDLINE | ID: mdl-36043882
15.
Olaparib and durvalumab in patients with relapsed small cell lung cancer (MEDIOLA): An open-label, multicenter, phase 1/2, basket study.
Lung Cancer
; 180: 107216, 2023 06.
Article
in English
| MEDLINE | ID: mdl-37146473
16.
Durvalumab in Combination With Olaparib Versus Durvalumab Alone as Maintenance Therapy in Metastatic NSCLC: The Phase 2 ORION Study.
J Thorac Oncol
; 18(11): 1594-1606, 2023 11.
Article
in English
| MEDLINE | ID: mdl-37390980
17.
Adavosertib with Chemotherapy in Patients with Primary Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer: An Open-Label, Four-Arm, Phase II Study.
Clin Cancer Res
; 28(1): 36-44, 2022 01 01.
Article
in English
| MEDLINE | ID: mdl-34645648
18.
Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance.
Clin Cancer Res
; 28(20): 4536-4550, 2022 10 14.
Article
in English
| MEDLINE | ID: mdl-35921524
19.
Homologous Recombination Repair Gene Mutation Characterization by Liquid Biopsy: A Phase II Trial of Olaparib and Abiraterone in Metastatic Castrate-Resistant Prostate Cancer.
Cancers (Basel)
; 13(22)2021 Nov 20.
Article
in English
| MEDLINE | ID: mdl-34830984
20.
The Combination of the PARP Inhibitor Olaparib and the WEE1 Inhibitor AZD1775 as a New Therapeutic Option for Small Cell Lung Cancer.
Clin Cancer Res
; 24(20): 5153-5164, 2018 10 15.
Article
in English
| MEDLINE | ID: mdl-29941481